Albireo Pharma (FRA:BDQM) Capex-to-Revenue : 0.00 (As of Sep. 2022)

Albireo Pharma Capex-to-Revenue Chart

Albireo Pharma Annual Data
	Trend	Sep12	Sep13	Sep14	Sep15	Sep16	Dec17	Dec18	Dec19	Dec20	Dec21
Capex-to-Revenue		Get a 7-Day Free Trial					161.00	0.01	0.06	0.01	0.01

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Capex-to-Revenue	Get a 7-Day Free Trial															-	-	0.03	0.08	-

Competitive Comparison of Albireo Pharma's Capex-to-Revenue

For the Biotechnology subindustry, Albireo Pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albireo Pharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Capex-to-Revenue falls into.

Albireo Pharma Capex-to-Revenue Calculation

Albireo Pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Albireo Pharma's Capex-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albireo Pharma  (FRA:BDQM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Albireo Pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description